Pharmacological Preconditioning with Diazoxide in the Experimental Hypothermic Circulatory Arrest Model

dc.contributor.authorHaapanen H
dc.contributor.authorArvola O
dc.contributor.authorHerajarvi J
dc.contributor.authorAnttila T
dc.contributor.authorTuominen H
dc.contributor.authorPuistola U
dc.contributor.authorKarihtala P
dc.contributor.authorKiviluoma K
dc.contributor.authorJuvonen T
dc.contributor.authorAnttila V
dc.contributor.organizationfi=tyks, vsshp|en=tyks, varha|
dc.converis.publication-id23906270
dc.converis.urlhttps://research.utu.fi/converis/portal/Publication/23906270
dc.date.accessioned2022-10-28T13:11:21Z
dc.date.available2022-10-28T13:11:21Z
dc.description.abstractBackground: Hypothermic circulatory arrest includes a remarkable risk for neurological injury. Diazoxide, a mitochondrial adenosine triphosphate-dependent potassium ion (K+ATP) channel opener, is known to have cardioprotective effects. We assessed its efficacy in preventing ischemic injury in a clinically relevant animal model.Methods: Eighteen piglets were randomized into a diazoxide group (n = 9) and a control group (n = 9). Animals underwent 60 minutes of hypothermic circulatory arrest at 18 degrees C. Diazoxide (5 mg/kg + 10 mL NaOH + 40 mL NaCl) was infused during the cooling phase. Metabolic and hemodynamic data were collected throughout the experiment. After 24-hour follow-up, whole brain, heart, and kidney biopsy specimens were collected for analysis.Results: Cerebellar Cytochrome-C and caspase-3 activation was higher in the control group (P = .02 and P = .016, respectively). Antioxidant activity tended to be higher in the diazoxide group (P = .099). Throughout the experiment, the oxygen consumption ratio was higher in the control animals (P-g = .04), as were the lactate levels (P-g = .02). Cardiac function tended to be better in diazoxide-treated animals.Conclusion: Diazoxide might confer neuroprotective effect as implied by the immunohistochemical analysis of the brain. Additionally, the circulatory effects of diazoxide were beneficial, supporting its neuroprotective effect.
dc.format.pagerangeE69
dc.format.pagerangeE76
dc.identifier.eissn1522-6662
dc.identifier.jour-issn1098-3511
dc.identifier.olddbid180337
dc.identifier.oldhandle10024/163431
dc.identifier.urihttps://www.utupub.fi/handle/11111/38364
dc.identifier.urnURN:NBN:fi-fe2021042716918
dc.language.isoen
dc.okm.affiliatedauthorDataimport, tyks, vsshp
dc.okm.discipline3121 Internal medicineen_GB
dc.okm.discipline3121 Sisätauditfi_FI
dc.okm.internationalcopublicationinternational co-publication
dc.okm.internationalityInternational publication
dc.okm.typeA1 ScientificArticle
dc.publisherFORUM MULTIMEDIA PUBLISHING, LLC
dc.publisher.countryUnited Statesen_GB
dc.publisher.countryYhdysvallat (USA)fi_FI
dc.publisher.country-codeUS
dc.relation.doi10.1532/hsf.1717
dc.relation.ispartofjournalHeart Surgery Forum
dc.relation.issue2
dc.relation.volume20
dc.source.identifierhttps://www.utupub.fi/handle/10024/163431
dc.titlePharmacological Preconditioning with Diazoxide in the Experimental Hypothermic Circulatory Arrest Model
dc.year.issued2017

Tiedostot

Näytetään 1 - 1 / 1
Ladataan...
Name:
1717-3918-1-PB.pdf
Size:
781.17 KB
Format:
Adobe Portable Document Format
Description:
Publisher's version